Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S7101 SCH772984 <1 mg/mL 14 mg/mL <1 mg/mL
S7921 DEL-22379 <1 mg/mL 89 mg/mL <1 mg/mL
S8701 MK-8353 (SCH900353) <1 mg/mL 50 mg/mL <1 mg/mL
S8708 AZD0364 <1 mg/mL 99 mg/mL 99 mg/mL
S7709 VX-11e <1 mg/mL 100 mg/mL 16 mg/mL
S8801 CC-90003 <1 mg/mL 92 mg/mL <1 mg/mL
S9306 Corynoxeine -1 mg/mL 76 mg/mL -1 mg/mL
s9102 Magnolin -1 mg/mL 83 mg/mL -1 mg/mL
S7334 ERK5-IN-1 <1 mg/mL 100 mg/mL 100 mg/mL
S7525 XMD8-92 <1 mg/mL 73 mg/mL <1 mg/mL
S8534 LY3214996 <1 mg/mL 27 mg/mL 16 mg/mL
S7752 Pluripotin (SC1) <1 mg/mL 100 mg/mL <1 mg/mL
S7854 Ulixertinib (BVD-523, VRT752271) <1 mg/mL 86 mg/mL 15 mg/mL
S7524 FR 180204 <1 mg/mL 65 mg/mL 2 mg/mL
S7554 Ravoxertinib (GDC-0994) <1 mg/mL 87 mg/mL 87 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations


SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.



DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ∼0.5 μM.


MK-8353 (SCH900353)

MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK1-ERK2-coupled assay).



AZD0364 is a pre-clinical ERK1/2 inhibitor with an IC50 of 0.6 nM for ERK2.



VX-11e is a potent, selective, and orally bioavailable ERK2 inhibitor with Ki of <2 nM, over 200-fold selective over other kinases tested.



CC-90003 is an irreversible inhibitor of ERK1/2 with IC50s in the 10-20 nM range and shows good kinase selectivity in a 258-kinase biochemical assay.



Corynoxeine, which could be isolated from Uncaria rhynchophylla, is a useful and prospective compound in the prevention and treatment for vascular diseases. It is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation.



Magnolin is a natural compound abundantly found in Magnolia flos targeting ERK1 (IC50=87 nM) and ERK2 (IC50=16.5 nM) and inhibits cell transformation induced by tumor promoters such as epidermal growth factor (EGF).



ERK5-IN-1 is a potent, and selective ERK5 inhibitor with IC50 of 162 nM.



XMD8-92 is a potent and selective BMK1/ERK5 inhibitor with Kd of 80 nM.



LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.


Pluripotin (SC1)

Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP with Kd values of 98 nM and 212 nM respectively. It maintains embryonic stem cell (ESC) self-renewal.


Ulixertinib (BVD-523, VRT752271)

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.


FR 180204

FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively. It is 30-fold less potent against the related kinase p38α and failed to inhibit any kinases(MEK1, MKK4, IKKα, PKCα, Src, Syc, and PDGFα) at less than 30 μM.


Ravoxertinib (GDC-0994)

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.